Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to LifeMD, Inc. (Nasdaq: LFMD) SEC filings, offering detailed insight into the company’s virtual primary care and pharmacy operations. As a U.S. public company, LifeMD files annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and current reports on Form 8‑K, along with other required documents. These filings describe its telehealth platform, pharmacy and compounding pharmacy activities, clinical programs across more than 200 conditions, and its evolution into a pure-play virtual care and pharmacy business following the divestiture of its majority interest in WorkSimpli Software LLC.
Through LifeMD’s 10‑K and 10‑Q reports, readers can review segment information, revenue composition, operating expenses, and risk factors associated with telehealth, pharmacy services, regulatory compliance, and collaborations with pharmaceutical manufacturers. The company’s filings also discuss its 50-state affiliated medical group, proprietary digital care platform, and affiliated pharmacy infrastructure, providing context on how its virtual care model is structured.
LifeMD’s Form 8‑K filings capture material events such as the sale of its majority stake in WorkSimpli, the establishment of a senior secured revolving credit facility with Citizens Bank, N.A., rescheduling of earnings releases, and the announcement of quarterly financial results. These current reports may also include press releases as exhibits, giving additional narrative detail on strategic transactions, capital structure decisions, and operational milestones.
The company has also filed a Form 12b‑25 (NT 10‑Q) to notify the SEC of a late quarterly filing due to the need for additional time to correct errors related to over-recognition of revenue in prior periods. In that notification, LifeMD stated that the adjustments would not affect its cash flow or cash position and that it was evaluating potential impacts on internal control over financial reporting.
On Stock Titan, LifeMD’s filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10‑K and 10‑Q reports, highlight key changes across periods, and surface important disclosures related to revenue recognition, segment reporting, credit facilities, preferred stock dividends, and significant transactions. Users can also review Form 4 and other ownership filings to track insider transactions and equity awards, with AI-generated explanations that clarify the nature of each transaction.
By combining raw SEC documents with AI-driven summaries and comparisons, this page helps investors, analysts, and researchers quickly understand LifeMD’s regulatory disclosures, financial reporting, and governance developments without manually parsing every filing.
LifeMD, Inc. entered into a Credit Agreement with Citizens Bank providing a senior secured revolving credit facility of up to $30 million to support potential corporate development and shareholder value initiatives.
The facility may be increased by up to an additional $20 million and matures on January 2, 2029. Interest is variable, based on either Term SOFR plus a margin of 1.50%–2.25% or an Alternate Base Rate plus a margin of 0.50%–1.25%, with a commitment fee of 0.225%–0.30% on unused amounts, all tied to the Consolidated Leverage Ratio.
Key financial covenants require a Consolidated Leverage Ratio at or below 2.50 to 1.00 and a Consolidated Interest Coverage Ratio of at least 3.00 to 1.00, beginning with the quarter ending March 31, 2026. LifeMD had not drawn any funds under the facility as of the January 2, 2026 closing.
LifeMD, Inc. reported that its Chief Marketing Officer, Jessica Friedeman, sold 15,000 shares of common stock on 12/09/2025 at a weighted average price of $3.6105 per share. The sale was executed through multiple transactions at prices ranging from $3.585 to $3.645.
Following this transaction, she beneficially owns 205,000 shares of LifeMD common stock, held directly. This disclosure describes a personal stock transaction by a senior executive and does not itself indicate any change in LifeMD’s business operations or financial results.
LifeMD, Inc. reported stronger Q3 2025 results, with total revenue rising to $60.2 million from $53.3 million a year earlier, driven by growth in telehealth and steady WorkSimpli software subscriptions. For the first nine months of 2025, revenue reached $187.0 million, up from $149.3 million in the prior-year period, while the operating loss narrowed sharply to $1.4 million from $14.4 million.
Net loss attributable to common stockholders improved to $4.6 million in the quarter and $7.9 million year-to-date, compared with $5.4 million and $18.8 million in the prior-year periods, despite ongoing preferred dividends of $2.3 million for the nine months. LifeMD generated $11.6 million of cash from operations year-to-date, repaid its remaining $14.0 million Avenue credit facility, and ended September 30, 2025 with $23.8 million in cash and positive stockholders’ equity of $3.4 million. Management states that existing cash should fund planned operations and capital needs for at least the next 12 months.
LifeMD, Inc. reported that it has released its financial results for the three and nine months ended September 30, 2025. The company disclosed in this report that a detailed press release with those results was issued on November 17, 2025 and is attached as Exhibit 99.1. The common stock trades on The Nasdaq Global Market under the symbol LFMD, and its 8.875% Series A Cumulative Perpetual Preferred Stock trades under the symbol LFMDP. This filing mainly serves to formally furnish the earnings press release under Item 2.02 of the Exchange Act.
LifeMD, Inc. (LFMD) filed a Form 12b-25 (NT 10-Q) to delay its Quarterly Report for the period ended September 30, 2025, stating it will file on or before the fifth calendar day following the due date. The company needs additional time to complete its financial statements and finalize adjustments to correct errors related to the over-recognition of revenue.
LifeMD identified approximately $4.6 million in cumulative over-recognized revenue across quarterly and annual periods between 2022 and June 30, 2025. The company states these adjustments will not affect its cash flow or cash position. It is also evaluating the potential impact on internal control over financial reporting. The company notes that its current and former independent registered public accounting firms have not audited, reviewed, or compiled the preliminary estimates.
LifeMD disclosed a scheduling change and accounting updates. The company rescheduled its third‑quarter 2025 earnings release and call to Monday, November 17, 2025, and expects to file a Form 12b‑25 for a late Form 10‑Q for the period ended September 30, 2025.
Management identified corrections after data system migrations affecting revenue recognition and related balance sheet accounts for the twelve months ended December 31, 2024 and the six months ended June 30, 2025. The cumulative impact is approximately $4.6 million, or about 1.4% of cumulative revenue for that period. The company states these adjustments will not materially change how reported revenue compared to guidance and will not affect cash flow or cash position.
LifeMD is evaluating potential implications for internal control over financial reporting. Preliminary determinations are subject to change as third‑quarter financials are prepared, and the company’s auditors have not performed procedures on these preliminary items.
LifeMD, Inc. completed the sale of 80% of WorkSimpli Software LLC to Lion Buyer, LLC, with signing and closing occurring simultaneously on November 4, 2025. The purchase price is based on an enterprise value of approximately $65.0 million, with $24.0 million paid at closing and up to an additional $28.0 million tied to future performance targets, for aggregate consideration of up to $52.0 million to the sellers.
At closing, the purchaser paid the estimated purchase price, with a portion held back as an adjustment holdback amount. The agreement includes customary representations, warranties, covenants, indemnification provisions, and closing deliverables. LifeMD also issued a press release announcing the transaction.
LifeMD (LFMD) director John R. Strawn Jr. reported an award of 22,365 restricted shares of common stock on October 6, 2025 at a price of $0. The filing states these restricted shares vest on June 1, 2026.
Following the grant, Strawn Jr. beneficially owned 413,001 shares directly and 60,000 shares indirectly through Strawn Pickens LLP.
LifeMD director Joan LaRovere reported a non‑derivative grant of 22,365 restricted shares of common stock acquired on 10/06/2025, increasing her beneficial holdings to 107,050 shares. The shares were granted at a price of $0, indicating they are restricted stock rather than a purchased award.
The grant carries a vesting condition: the restricted shares vest on June 1, 2026. This filing records a direct ownership change by a company insider; no options, conversions, or derivative instruments were reported.
LifeMD (LFMD) reported an insider equity award. A director acquired 22,365 shares of common stock on 10/02/2025 at a price of $0, as disclosed on Form 4. The filing notes this was a grant of restricted shares that vests on June 1, 2026. Following the award, the director beneficially owns 273,413 shares, held directly.